Last update Aug. 20, 2022

Bepridil Hydrochloride

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

It is a calcium channel blocker chemically unrelated to others such as diltiazem, nifedipine or verapamil. It is used in the treatment of angina pectoris. Oral administration.

At latest update no published data were found on excretion into breast milk.

Its high plasma protein-binding capacity makes it unlikely the passage to the breast milk, however, it has a very long elimination time.

It can cause QT prolongation on the EKG and serious cardiac arrhythmias. It has been withdrawn from the market in many countries.

During breastfeeding an alternative drug that is known to be safer is preferred, especially during the neonatal period and in case of a premature infant.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Bepridil Hydrochloride in other languages or writings:

Group

Bepridil Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Bepridil Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 60 %
Molecular weight 421 daltons
Protein Binding 99 %
VD 8 l/Kg
Tmax 2 - 3 hours
T½ 42 (24 - 50) hours

References

  1. Shiga T, Hashiguchi M, Naganuma M, Suzuki A, Hagiwara N. Contributing factors to the apparent clearance of bepridil in patients with paroxysmal or persistent atrial fibrillation: analysis using population pharmacokinetics. Ther Drug Monit. 2013 Abstract
  2. Hasegawa GR. Nicardipine, nitrendipine, and bepridil: new calcium antagonists for cardiovascular disorders. Clin Pharm. 1988 Abstract
  3. Lesko LJ, Benotti JR, Alpert JS, Brady PM, McCue JE, Weiner BH, Ockene IS. Pharmacokinetics of intravenous bepridil in patients with coronary disease. J Pharm Sci. 1986 Abstract

Total visits

3,631

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM